Lymphoma is a group of malignant tumors originating from the lymphohematopoietic system. It is mainly classified into two categories: Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), among which Hodgkin lymphoma has a relatively better prognosis.
Worldwide, more than 500,000 new cases of lymphoma are diagnosed each year. Early symptoms are often subtle and easily missed — but timely medical evaluation can still open a window for curative outcomes, so seeking help as soon as possible is essential.
China sees over 100,000 new lymphoma cases each year — one of the world's largest patient populations. At Fosun Health, this extraordinary case volume has given our expert teams a depth of experience that ensures precision in every aspect of care, from accurate pathological subtyping to targeted therapy and immunotherapy.
Every lymphoma program has chemotherapy, radiation, and antibodies. Here is what makes ours different:
"They said it is in my neck, chest, and abdomen. It is a blood cancer—has it taken over my whole body? Is this hopeless?"
The challenge: Lymphoma is a systemic disease by nature. A PET-CT often lights up multiple nodal stations and sometimes the bone marrow. Patients panic: "It is everywhere." But lymphoma is not solid-tumor metastasis. Stage IV lymphoma is often highly curable—and early-stage disease, even with bulky masses, is curable with precision combinations.
Our answer: Stage and subtype matched therapy that attacks the biology, not the geography:
- Diffuse Large B-Cell Lymphoma (DLBCL): R-CHOP (rituximab + cyclophosphamide, doxorubicin, vincristine, prednisone) remains the curative backbone for most patients. For double-hit/triple-hit (MYC/BCL2/BCL6 rearranged) high-risk disease, we escalate to DA-EPOCH-R or polatuzumab-based regimens—improving cure rates in the most aggressive subtype.
- Hodgkin Lymphoma: ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine) or escalated BEACOPP achieves >80% cure rates in advanced-stage disease. PET-adapted therapy—de-escalating if early PET is clean—spares toxicity without sacrificing cure.
- Indolent Lymphomas (Follicular, Marginal Zone): When treatment is needed, rituximab + bendamustine or lenalidomide-based combinations control disease for years. For localized disease, CyberKnife M6 stereotactic radiotherapy delivers curative-intent radiation in 1–5 sessions with 0.1mm precision—no systemic chemotherapy needed.
- Mantle Cell Lymphoma: BTK inhibitors (ibrutinib, zanubrutinib) combined with chemotherapy or as maintenance transform outcomes—particularly the China-original zanubrutinib, which demonstrates superior selectivity and tolerability.
- NK/T-Cell Lymphoma: Asparaginase-containing regimens (SMILE) combined with early radiotherapy achieve curative outcomes for this EBV-driven, geographically prevalent Asian subtype.
What this means for you: "Stage IV" in lymphoma does not mean what it means in lung or liver cancer. Your cure potential depends on subtype and molecular biology—not on how many lymph nodes are lit up. We match the weapon to the tumor.
"I have heard chemotherapy for lymphoma is brutal. Will I be vomiting nonstop, lose my hair, and end up in isolation with zero immunity? How do I survive the treatment itself?"
The challenge: Lymphoma regimens like R-CHOP, ABVD, and BEACOPP are among the most intensive in oncology. They annihilate malignant lymphocytes—but also crush normal neutrophils, red cells, and platelets. Mouth and gut mucosa sloughs off. Nausea, neuropathy, and fatigue can make patients beg to stop. And the psychological toll of hair loss and isolation is profound.
Our answer: A protective and supportive infrastructure that keeps you strong enough to finish every planned cycle—the single most important predictor of cure:
- Precision Anti-Emetic Prophylaxis: NK-1 receptor antagonists + 5-HT3 blockers + dexamethasone triple-combination prophylaxis prevents >90% of chemotherapy-induced vomiting before it starts.
- G-CSF & Blood Component Support: Pegfilgrastim on-body injector auto-administers 27 hours post-chemo, preventing febrile neutropenia. Single-donor platelet apheresis prevents bleeding. You stay out of the emergency room.
- Infection Shield: Prophylactic antibiotics, antivirals, and antifungals are deployed during the neutropenic window—not waiting for fever. High-frequency CMV/EBV viral load monitoring catches viral reactivation before it becomes pneumonia or hepatitis.
- Tumor Hyperthermia as Radiosensitizer: For bulky nodal masses receiving concurrent chemoradiation, regional hyperthermia to 40–43°C disrupts lymphoma cell membranes and sensitizes them to both radiation and chemotherapy—a force multiplierthat shrinks masses faster without increasing toxicity. Particularly effective for the chest, abdomen, and superficial nodal disease.
- Integrative TCM: "Toxicity Reduction + Immune Rebuild"： Evidence-informed herbal formulations reduce chemotherapy-induced nausea, protect gastrointestinal mucosa, support white blood cell and platelet recovery, and mitigate peripheral neuropathy from vincristine. The goal: complete every dose on schedule, without delay or dose reduction.
What this means for you: Chemotherapy is demanding, but it does not have to be unbearable. Our protective system—anti-nausea, growth factors, infection prevention, thermal sensitization, and integrative support—exists for one purpose: to ensure you finish your full curative course, on time, without dropping out.
"My neck and chest lymph nodes are so swollen I can barely swallow or breathe. Or the disease has eaten into my hip bone and the pain is excruciating. Can you help me first?"
The challenge: Aggressive lymphomas can form massive mediastinal or retroperitoneal nodal conglomerates that compress the trachea, superior vena cava, ureters, or bile ducts—causing stridor, facial swelling, renal failure, or jaundice. Bone involvement causes fracture-risk pain that opioids barely touch. Patients feel they are being strangled from the inside.
Our answer: Rapid decompression and pain control without open surgery:
- CyberKnife M6 for Bulky Masses: For massive mediastinal or retroperitoneal nodal masses compressing critical structures, 0.1mm sub-millimeter stereotactic radiosurgery converges radiation from thousands of angles—rapidly shrinking the mass and relieving compression within days. 1–5 sessions. No incision. Immediate palliation while systemic therapy takes full effect.
- Stenting for Compression Syndromes: For SVC syndrome (facial/arm swelling from venous compression), endovascular stenting restores venous drainage within hours. For ureteral or biliary compression from bulky nodes, double-J ureteral or biliary stentsreopen blocked channels—protecting kidney and liver function.
- Image-Guided Ablation for Bone Lesions: For painful, fracture-risk bone deposits, cryoablation destroys the tumor while naturally numbing pain fibers—providing rapid, durable pain relief. Combined with cementoplasty for weight-bearing bones to prevent collapse.
- Celiac Plexus & Regional Nerve Blockade: For retroperitoneal or pelvic lymphoma invading nerve plexuses, image-guided neurolysis interrupts pain signaling—reducing opioid dependence and restoring sleep.
What this means for you: When lymph nodes are strangling your airway or veins, or bone pain is breaking your spirit, we can shrink the mass, reopen the blocked channel, freeze the painful lesion, or block the nerve signal—giving you immediate relief and the strength to continue curative therapy.
"My DLBCL has relapsed after R-CHOP and salvage chemo. Or my follicular lymphoma is no longer responding. Is there truly anything left? And can I possibly afford CAR-T?"
The challenge: Relapsed or refractory aggressive lymphoma is one of oncology's most feared scenarios. Standard salvage chemotherapy often fails. CAR-T cell therapy—transformative for B-cell lymphomas—costs upwards of $400,000–$500,000 in the US and Europe. In many regions, it remains unavailable entirely. Patients feel abandoned at the exact moment when the most powerful therapies exist.
Our answer: In China, cellular and targeted immunotherapy is not a distant dream—it is an accessible reality:
- CD19 CAR-T Cell Therapy: Axicabtagene ciloleucel (Yescarta) and tisagenlecleucel (Kymriah) are approved and commercially available in China for relapsed/refractory large B-cell lymphoma. For appropriately selected patients, complete remission rates exceed 50%, with durable remissions in 30–40%. Our cell processing facility and clinical team manage the full chain—from leukapheresis to infusion to CRS/ICANS monitoring.
- Bispecific T-Cell Engagers (BiTEs): Glofitamab (CD20×CD3) and epcoritamab are approved in China and offer off-the-shelf cellular immunotherapy—no need to manufacture cells from your own blood. Subcutaneous administration with manageable toxicity profiles.
- Antibody-Drug Conjugates (ADCs): Polatuzumab vedotin (CD79b-ADC) and loncastuximab tesirine (CD19-ADC)provide targeted cytotoxic delivery for relapsed DLBCL and other B-cell lymphomas.
- BTK & PI3K Inhibitors: For relapsed mantle cell, marginal zone, and follicular lymphomas, zanubrutinib, ibrutinib, and idelalisib are in routine use—offering oral, outpatient disease control.
- Cost Advantage & China-Original Agents: CAR-T and bispecific therapy in China are delivered at 30%–50% of the cost in Europe or the US—with identical cell manufacturing quality. Additionally, China-original CAR-T constructs and CD3/CD20 bispecific antibodies are in advanced clinical development, expanding access further.
Guided by NGS-based molecular profiling and physicians who have managed hundreds of relapsed lymphoma cases through cellular and targeted salvage.
What this means for you: A relapse after first-line therapy is not a terminal event. Your CD20, CD19, or CD79b status opens a direct path to CAR-T, bispecific antibodies, or ADCs that are available here, now—at a cost that makes this transformative therapy genuinely accessible.
When standard therapies reach their limit, we provide rapid access to China's full portfolio of Phase III clinical trials—therapies typically 3–5 years ahead of availability elsewhere. NGS-based molecular matching identifies trials targeting your specific mutation. Every enrollment is ethics-approved with full medical supervision.
Our TCM program runs alongside your primary treatment as an "immune and vitality optimizer":
Toxicity Reduction: Herbal formulations help protect bone marrow function, ease chemotherapy-induced nausea and vomiting, reduce cancer-related fatigue, support platelet and white blood cell recovery, and mitigate peripheral neuropathy.
Efficacy Enhancement: Selected preparations may improve tumor sensitivity to chemotherapy or radiation.
Acupuncture provides additional support for pain, nausea, fatigue, and post-treatment neuropathy. The goal: reduce treatment burden, protect your immune function, and keep you strong enough to complete every planned cycle—and move forward to cure.
Every lymphoma case is reviewed by a panel comprising hematology/oncology, radiation oncology, pathology/flow cytometry, radiology/nuclear medicine (PET-CT), interventional radiology, clinical nutrition, and integrative medicine specialists. Lymphoma decisions are uniquely complex: histologic subtype confirmation; PET-adapted therapy de-escalation; bulky disease needing local radiotherapy; sequencing of chemoimmunotherapy, targeted agents, CAR-T, and bispecifics through lines of resistance; and management of post-CAR-T cytokine release syndrome.
The MDT convenes within 48 hours of complete documentation. Your plan is a consensus decision optimized for your lymphoma subtype, molecular profile, stage, age, and your priorities.
Diagnosis:
Stage IIIB Classical Hodgkin Lymphoma, Nodular Sclerosis Subtype
Treatment Plan:
Combination chemotherapy followed by response assessment using PET-CT and subsequent CyberKnife radiotherapy for residual mediastinal disease.
After two treatment cycles, PET-CT demonstrated marked shrinkage of the mediastinal mass with near-complete metabolic response. Following completion of systemic therapy, consolidative CyberKnife radiotherapy was administered, resulting in complete metabolic remission.
Outcome:
Symptoms remained well controlled; however, PET-CT performed 18 months later revealed mild localized metabolic recurrence within the mediastinum.
Following multidisciplinary team (MDT) consultation, salvage chemotherapy was initiated. The patient subsequently underwent CAR-T cell therapy. One month after CAR-T infusion, PET-CT confirmed complete metabolic remission. The patient successfully returned to normal work and daily life.
Led by Dr. Yang Jun, Prof. Luo Pengfei, and Prof. Chen Tao, the Fosun Oncology Center brings together more than 20 world-class medical experts, each with over a decade of extensive oncology experience. Supported by a comprehensive range of advanced therapies — including robotic surgery, precision radiotherapy, minimally invasive intervention, CAR-T cell therapy, and Tumor Treating Fields (TTFields) — the center delivers one-stop, integrated cancer care designed to make treatment more accessible, efficient, and high-quality for every patient.
Key Highlights
- Over 60,000 annual oncology patient admissions across Fosun’s major international hospitals in 2025
More than 17,000 cumulative TACE procedures completed between 2023 and 2025 at Fosun Hospital Guangzhou alone, with international patients accounting for over 10% of total cases
- More than 1,000 successful CyberKnife treatments performed, demonstrating world-class expertise in precision radiotherapy
- A 29.3% five-year survival rate achieved for Glioblastoma Multiforme (GBM) through combined TTFields therapy, representing a significant improvement over the 4.7% baseline
Core Services
- Robotic surgery
- Precision radiotherapy
- Minimally invasive intervention
- CAR-T cell therapy
- Tumor Treating Fields (TTFields)
- Medical oncology
- PET/CT imaging
- Pulmonary nodule diagnosis
- VIP inpatient wards
- Integrated oncology clinics
- Traditional Chinese medicine for oncology
- Cancer screening and early detection
- Genetic testing and counseling
Founded in 1992, Fosun has grown over the past three decades into a global innovation-driven consumer group. In 2007, Fosun International Limited was listed on the Main Board of the Hong Kong Stock Exchange (stock code: 00656.HK). As one of the few Chinese enterprises with strong global operational and investment capabilities, Fosun has developed substantial technological expertise and innovation capacity across multiple industries.
Established in 2010, Shanghai Fosun Health Technology is dedicated to building a world-renowned healthcare group in Asia. Today, the group operates 19 affiliated medical institutions across Foshan, Guangzhou, Shenzhen, Zhuhai, Shanghai, and other major cities, with a total of 6,600 hospital beds and 9 Internet Hospital licenses. Fosun Health ranks No. 1 among China’s private comprehensive medical groups. Its flagship institution, Fosun Foshan Chancheng Hospital, has ranked first among private hospitals in China for eight consecutive years and was honored with the 2026 Global Health Asia-Pacific “Oncological Medical Service Provider of the Year” award.
As the flagship hospital of Fosun Health, Fosun Foshan Chancheng Hospital was founded in 1958. The hospital currently hosts 28 key specialty development programs, including 2 provincial-level, 13 municipal-level, and 13 district-level key specialties. Its services span 22 medical disciplines, including spinal orthopedics, traditional Chinese medicine gynecology, obstetrics and gynecology, cardiovascular medicine, clinical laboratory medicine, anesthesiology, pediatrics, critical care medicine, ultrasound medicine, rehabilitation medicine, general practice, general surgery, and urology.
The hospital is equipped with globally advanced medical technologies, including the CyberKnife system and the Da Vinci Surgical Robot. It has 1,750 approved hospital beds and a multidisciplinary team of more than 2,800 medical professionals. The hospital records nearly 3.19 million outpatient visits annually and more than 67,000 inpatient discharges each year.
Fosun Foshan Chancheng Hospital has received numerous prestigious recognitions, including:
Global Health Asia-Pacific “Traditional Chinese Medicine Hospital of the Year”
Global Health China “Hospital of the Year”
No. 1 ranking on the GAHA Top 500 Private Hospitals in China list for eight consecutive years
The hospital has also been recognized as:
A National Model Unit for Improved Medical Services
A National Drug Clinical Trial Institution (GCP)
A National Standardized Residency Training Base
Established in 2003, Guangzhou Fosun Chancheng Hospital specializes in cardiovascular medicine, oncology, and neurosciences. The hospital has established a National Chest Pain Center, Stroke Center, Trauma Center, and MDT Center, supporting the development of emergency medicine, obstetrics and gynecology, intensive care, anesthesiology, gastroenterology, general surgery, urology, and general practice.
The hospital operates more than 800 inpatient beds and 48 clinical and medical technology departments, supported by a team of over 880 healthcare professionals.
Guangzhou Fosun Chancheng Hospital has received several honors and industry recognitions, including:
EMBA Innovation Practice Base
Guangdong Private Medical Reform & Innovation Brand
Guangdong Private Medical Industry Pioneer Brand
Outstanding Brand Hospital for Medical Investment Contribution
Upload your lymph node biopsy pathology report (including IHC), PET CT images, blood work, FISH for MYC/BCL2/BCL6, and NGS results (EZH2, TP53, NOTCH1, etc.). Our multidisciplinary lymphoma team (hematologists, radiation oncologists, immunotherapists) will provide a personalized treatment plan—including subtype confirmation, risk stratification, CAR T candidacy, and transplant evaluation—within 48 hours.
